Home » Articles » Policosanal - Natural, Safe, and Better Than Cholesterol Drugs!

Policosanal - Natural, Safe, and Better Than Cholesterol Drugs!

Drug companies and government agencies are now urging millions more Americans to lower cholesterol with the drugs called "statins." But statins pose risks too frightening to ignore—ranging from high blood sugar and gallstones, to kidney failure and a deadly muscle-wasting disease. Meanwhile, one nutrient outperforms leading statins, and is safe for virtually anyone. Can this remarkable find stop heart disease in its tracks? Read on …

It’s never too late to protect and rejuvenate your heart health. One of the most effective things you can do—right now—is to lower your cholesterol.

-Sponsored Ads-

Even small changes mean a big difference for your health and longevity: every 10% drop in cholesterol lowers your risk of heart attack by 25%.¹ That's a difference that can save lives. In fact, lowering cholesterol is now proven to be a key to living a longer, more energetic life.²

Thanks to the wildly popular cholesterol drugs known as "statins," it's easier than ever to control cholesterol. Only problem is, it may be more dangerous than ever.

Millions of statin prescriptions are written every year, for about $60 to $120 per month. The statins, also known as "HMG-CoA reductase inhibitors," include Lipator, Baycol, Crestor, Lescol, Mevacor, Pravachol, and Zocor. They work by blocking the production of cholesterol in the liver itself, which lowers LDL (the "bad") cholesterol and slightly raises HDL (the "good") cholesterol.

Numerous tests show the natural policosanol preparation:

Controls cholesterol as well as—or better than—cholesterol drugs

Has no side effects, zero risks—even at "mega" doses

Stimulates your body's own "cholesterol flush"—for lifetime prevention

Protects post-menopausal women, even when diet fails

Protects elderly from heart disease

Fights high cholesterol in diabetics—where cholesterol drugs pose risks

Makes artery cells stronger, healthier, and resistant to plaque

Slashes risk of deadly clots throughout your entire body

Relieves muscle pain caused by poor circulation

But here's the problem:

The very same medications designed to protect and support a long, healthy life are now proven to pose potentially life-threatening risks.

What's worse, some of the so-called top-tier statins fail to fend off a heart attack, stroke, or death ... while others may actually increase hidden risks to your heart.

But there is a way to get the protective benefits of lower cholesterol, without the risks of prescription cholesterol-lowering drugs.

You can erase dangerous cholesterol from your bloodstream, naturally.

And, you can avoid the frightening side effects of cholesterol drugs.

One nutrient works wonders for your cholesterol and heart health, without risk. Health-conscious individuals of all ages are taking it with excellent results. That includes post-menopausal women, the elderly with inherited high cholesterol, men and women with existing heart disease, those who suffer angina (chest pain), those with leg cramps, diabetics, and even those who just want to maintain healthy cholesterol levels and promote higher energy.

Get safe, fast results: Lower LDL 29% … Lower total cholesterol 21% Increase healthy HDL by 15% or more

This nutrient also strengthens your arteries, and—amazingly—it promotes your body's natural cholesterol-lowering ability for a lifetime of protection and rejuvenation. Studies show it can even reverse the progression of artery and heart disease.³⁴

HEART HEALTH FACT #1:

Heart disease is the number one killer of men and women over 40.

HEART HEALTH FACT #2:

One in two Americans has high cholesterol—a prime cause of hardened, narrowed arteries, which leads to heart disease, heart attack, and stroke.

HEART HEALTH FACT #3:

Leading cholesterol drugs are linked to new and FRIGHTENING side effects, disease, and death.

HEART HEALTH FACT #4:

One surprising alternative lowers dangerous cholesterol up to 29% … risk-free.

In numerous scientifically controlled studies, this single nutrient has outperformed leading cholesterol drugs, and has been proven to be completely free of the toxic dangers caused by the statins. Anyone who takes cholesterol drugs or who is about to start should know about this well-documented alternative.

It's available now … and it's never been more urgent. Especially today, when researchers and international medical journals are asking:

Are statins really safe enough for long-term use?
Can you really "live with" the side effects?
Do statin drugs really reduce your risk of death?

In 2002, the American College of Cardiology, the American Heart Association, and the National Heart, Lung and Blood Institute warned doctors about a disturbing risk caused by statins. That risk is a toxic, potentially deadly, muscle disorder called Rhabdomyolysis.

But by the time that warning came, it was already too late for untold numbers of statin users. In August 2001, the cholesterol drug Baycol®, made by Bayer Pharmaceutical, was withdrawn from the market after it was linked to 40 deaths. In January 2002, Baycol was officially linked to an additional 100 deaths.5 Crestor® has also been directly linked to this muscle-wasting disease.6 Scientific reviews conclude that all statins carry this risk.⁷

For some, muscle pain and toxicity can happen rapidly. For others it may take months or years to build up in the body, leaving a trail of clues your doctor may not recognize—including muscle and joint pains, muscle weakness, and an increase in a chemical called creatine kinase, which often indicates future kidney failure, heart damage, and death.⁸

Another cholesterol drug called Zocor® (Simvastatin), may increase risks to your heart. Zocor saps your body of very important antioxidants and nutrients, including CoQ10 which is heart-protective. In fact, congestive heart failure patients typically have low levels of CoQ10.⁹ Zocor has also been shown to increase blood sugar levels by 13% which increases risk for insulin-resistance and Type II diabetes. And, as recently reported at the European Society of Cardiology, Zocor fails to prevent heart attack, stroke, hospital readmission, and death in heart patients who've had angioplasty.¹⁰

Drug companies caught red-handed

Cholesterol drug manufacturers such as Merck, AstraZenica and Pfizer earned $26 billion worldwide last year, even as evidence continued to mount against the statins.

Statins offer little or NO protection for women without heart disease from heart attack, heart disease "events," or death.¹¹
Statins may reduce risk of heart attack in the elderly, but they may fail to protect against stroke, and can cause new cases of cancer.¹²
Statins can cause liver damage or liver failure. You're at greater risk if you have other diseases such as diabetes or kidney failure, if you're taking other medications, or if you've recently had surgery. Other high risk groups include the elderly and those who drink heavily.
Page 1 of 2 pages 1 2 >

Editor's Note:

The natural health solutions described in this article are available through many on-line retailers including those listed below. By clicking these links you help support the important alternative health research we provide.

Visit www.amazon.com – a great way to find competitive deals on supplements offered by many different manufacturers.

Visit www.hfn-usa.com – when commitment to quality and freshness is important, this factory direct solution is preferred by many of our readers.

This article is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a physician before embarking on a dietary supplement program.

References
1. www.loweringcholesterol.net/show/lower-ldl-cholesterol
  
  Link ↑
2. www.americanheart.org/presenter.jhtml?identifyer=4524
  
  ↑
3. Janikula M. Policosanol: A new treatment for cardiovascular disease?Altern Med Rev 2002 Jun;7(3):203-17.
  
  Abstract ↑
4. Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65.
  
  Abstract ↑
5. www.msnbc.com/news/690373.asp
  
  ↑
6. www.citizen.org/pressroom/release.cfm?ID=1657
  
  Link ↑
7. MA Omar, JP Wilson, and TS Cox, "Rhabdomyolysis and HMG-CoA reductase inhibitors" Ann. Pharmacother., Sep 2001; 35:1096 - 1107.
  
  ↑
8. Stephen G. Ellis, MD; Derek Chew, MBBS; etal. Death Following Creatine Kinase-MB Elevation After Coronary Intervention.American Heart Association, Inc. Published online before print August 19, 2002, doi:10.1161/01.CIR.0000028146.71416.2E
  
  Abstract ↑
9. Alternative Medicine Guide: Heart Disease, Stroke & High Blood Pressure, Future Medicine Publishing, Tiburon, California, 1998. 31-32.
  
  ↑
10. http://heartdisease.about.com/b/a/109906.htm
  
  Link ↑
11. Judith M. E. Walsh, MD, MPH; Michael Pignone, MD, MPH. Drug Treatment of Hypelipidemia in Women. JAMA. 2004;291:2243-2252.
  
  ↑
12. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623-30.
  
  Abstract ↑
13. http://www.laskerfoundation.org/reports/html/heartdisease.html
  
  ↑
14. www.americanheart.org/presenter.jhtml?identifyer=4506
  
  ↑
15. Menendez R, Amor AM, Rodeiro I, et al, Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arc Med Res2001 Jan-Feb;32(1):8-12.
  
  Abstract ↑
16. Menendez R, Amor AM, Gonzalez RM, Fraga V, Mas R. Effect of Policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996;29(2):253-7.
  
  Abstract ↑
17. Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65.
  
  Abstract ↑
18. Menendez R. Fernandez SI, Del Rio A, et al, Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res. 1994;27(3-4):199-203.
  
  Abstract ↑
19. Batista J, Stusser R, Saez F, Perez B. Effect of Policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. "… a clinical tendency to improve their CHD, in comparison with the placebo group." Int J Clin Pharmacol Ther1996 Mar;34(3):134-7.
  
  Abstract ↑
20. Janikula M. Policosanol: A new treatment for cardiovascular disease? Altern Med Rev 2002 Jun;7(3):203-17.
  
  Abstract ↑
21. Mirkin A, Mas R, Martinto M, Boccanera R, Robertis A, Poudes R, Fuster A, Lastreto E, Yanez M, Irico G, McCook B, Farre A. Efficacy and tolerability of Policosanol in hypercholesterolemic post-menopausal women. Int J Clin Pharmacol Res 2001;21(1):31-41.
  
  Abstract ↑
22. Janikula M. Policosanol: a new treatment for cardiovascular disease?Altern Med Rev 2002 Jun;7(3):203-17.
  
  Abstract ↑
23. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65.
  
  Abstract ↑
24. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of Policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001 Mar;56(3):M186-92.
  
  Abstract ↑
25. Castano G, Mas R, Fernandez JC, Fernandez L, Illnait J, Lopez Effects of Policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 2002;3(3):159-72.
  
  Abstract ↑
26. Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L, Fernandez JC. Effects of successive dose increases of Policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14(1):27-33.
  
  Abstract ↑
27. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Comparative study of the efficacy and tolerability of Policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res1999;19(4):117-27.
  
  Abstract ↑
28. Prat H, Roman O, Pino E. Comparative effects of Policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia [Article in Spanish] Rev Med Chil 1999 Mar;127(3):286-94.
  
  Abstract ↑
29. Mas R, Castano G, Illnait J, Fernandez L, Fernandez J, Aleman C, Pontigas V, Lescay M. Effects of Policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999 Apr;65(4):439-47.
  
  Abstract ↑
30. Canetti M, Moreira M, Mas R, Illnait J, Fernandez L, Fernandez J, Diaz E, Castano G. A two-year study on the efficacy and tolerability of Policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15(4):159-65.
  
  Abstract ↑
31. Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L, Fernandez JC. Effects of successive dose increases of Policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14(1):27-33.
  
  Abstract ↑
32. Arruzazabala ML, Molina V, Mas R, Fernandez L, Carbajal D, Valdes S, Castano G Antiplatelet effects of Policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin Exp Pharmacol Physiol 2002 Oct;29(10):891-7.
  
  Abstract ↑
33. Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65.
  
  Abstract ↑
34. Aleman CL, Puig MN, Elias EC, Ortega CH, Guerra IR, Ferreiro RM, Brinis F.Carcinogenicity of Policosanol in mice: an 18-month study. Food Chem Toxicol 1995 Jul;33(7):573-8.
  
  Abstract ↑
35. Aleman CL, Mas Ferreiro R, Noa Puig M, Rodeiro Guerra I, Hernandez Ortega C, Capote A. Carcinogenicity of Policosanol in Sprague Dawley rats: a 24 month study. Teratog Carcinog Mutagen 1994;14(5):239-49.
  
  Abstract ↑
36. Janikula M. Policosanol: a new treatment for cardiovascular disease?Altern Med Rev 2002 Jun;7(3):203-17.
  
  Abstract ↑
37. Rodriguez MD, Garcia H. Evaluation of peri- and post-natal toxicity of Policosanol in rats. Teratog Carcinog Mutagen 1998;18(1):1-7.
  
  Abstract ↑
38. Rodriguez MD, Garcia H. Teratogenic and reproductive studies of Policosanol in the rat and rabbit. Teratog Carcinog Mutagen1994;14(3):107-13.
  
  Abstract ↑
39. Castano G, Mas R, Fernandez L, Illnait J, Mesa M, Alvarez E, Lezcay M."Comparison of the Efficacy and Tolerability of Policosanol with Atorvastatin in Elderly Patients with Type II Hypercholesterolaemia." Drugs Aging 2003;20(2):153-63.
  
  Abstract ↑
40. Mirkin A, Mas R, Martinto M, Bocconera R, Robertis A, Poudes R, Fuster A, Lastreto E, Yanez M, Irico G, McCook B, Farre A. Efficacy and tolerability of Policosanol in hypercholesterolemic post-menopausal women. Int J Clin Pharmacol Res 2001;21(1):31-41.
  
  Abstract ↑
41. Castano G, Mas R, Fernandez L, Fernandez JC, Illnait J, Lopez LE, Alvarez E. "Effects of Policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000 Jun;14(3):187-95.
  
  Abstract ↑
42. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of Policosanol in older patients with type II hypercholesterolaemia and high coronary risk. J Gerontol A Biol SciMed Sci 2001 Mar;56(3):M186-92.
  
  Abstract ↑
43. Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L, Fernandez JC. Effects of successive dose increases of Policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14(1):27-33.
  
  Abstract ↑
44. Castano G, Mas R, Fernandez L, Illnait J, Lopez E. Effects of Policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 2002;3(3):159-72.
  
  Abstract ↑
45. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Comparative study of the efficacy and tolerability of Policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res1999;19(4):117-27.
  
  Abstract ↑
46. Stusser R, Batista J, Padron R, Sosa F, Pereztol O. Long-term therapy with Policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients. Int J Clin Pharmacol Ther 1998 Sep;36(9):469-73.
  
  Abstract ↑
47. Castano G., Mas R. A double-blind, placebo-controlled study of the effects of Policosanol in patients with intermittent claudication.Angiology 1999 Feb;50(2):123-30.
  
  Abstract ↑
48. Castano G, Mas Ferreiro R, Fernandez L, Gamez R, Illnait J, Fernandez C. A long-term study of Policosanol in the treatment of intermittent claudication. Angiology 2001 Feb;52(2):115-25.
  
  Abstract ↑
49. Castano G, Mas R, Fernandez JC, Fernandez L, Illnait J, Lopez E. Effects of Policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 2002;3(3):159-72.
  
  Abstract ↑
50. Janikula M. Policosanol: A new treatment for cardiovascular disease?Altern Med Rev 2002 Jun;7(3):203-17.
  
  Abstract ↑
51. Prat H., Roman O. Comparative effects of Policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. Rev Med Chil 1999 Mar;127(3):286-94.
  
  Abstract ↑
52. Menendez R, Mas R, Amor AM, Gonzalez RM, Fernandez JC, Rodeiro I, Zayas M, Jimenez S. Effects of Policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000 Sep;50(3):255-62.
  
  Abstract ↑
53. Fraga V, Menendez R, Amor AM, Gonzalez RM, Jimenez S, Mas R. Effect of Policosanol on in vitro and in vivo rat liver microsomal lipid peroxidation. Arch Med Res 1997 Autumn;28(3):355-60.
  
  Abstract ↑
54. Gouni-Berthold I, Berthold HK. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65.
  
  Abstract ↑
55. Castano G, Mas R, Arruzazabala ML, Noa M, Illnait J, Fernandez JC, Molina V, Menendez A.Effects of Policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res1999;19(4):105-16.
  
  Abstract ↑
56. Arruzazabala ML, Mas R, Molina V, Carbajal D, Mendoza S, Fernandez L, Valdes S. Effect of Policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React1998;20(4):119-24.
  
  Abstract ↑
57. Noa M, Mas R, Mesa R. A comparative study of Policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery.Pharmacol Res 2001 Jan;43(1):31-7.
  
  Abstract ↑
58. Noa M, Mas R. Effect of Policosanol on lipofundin-induced atherosclerotic lesions in rats. J Pharm Pharmacol 1995 Apr;47(4):289-91.
  
  Abstract ↑
59. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.JAMA. 1995; 274:1049-57.
  
  Abstract ↑
60. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocystinemia in humans. J Nutr. 1994; 124:1927-33.
  
  ↑
61. Chait A, Malinow MR, Nevin DN, Morris CD, Eastgard RL, Kris-Etherton P, Pi-Sunyer FX, Oparil S, Resnick LM, et al. Increased dietary micronutrients decrease serum homocysteine concentrations in patients at high risk of cardiovascular disease. Am J Clin Nutr. 1999; 70(5):881-7.
  
  Abstract ↑
62. Arnadottir, M., Brattistrom, O., Simonsen, H, et al, The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine co in dialysis patients, Clin Nephrol, 1993, 40:236-240.
  
  ↑
63. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.JAMA. 1997; 277(22):1775-81.
  
  Abstract ↑
64. El-Enein AMA, Hafez YS, Salem H, Abdel M. The role of nicotinic acid and inositol hexaniacinate as anticholesterolemic and antilipemic agents. Nutr Reports Int 1983;28:899-911.
  
  ↑
65. Lei XL, Chiou GC. Cardiovascular pharmacology of Panax notoginseng (Burk) F.H. Chen and Salvia miltiorrhiza. Am J Chin Med. 1986; 14(3-4): 145-52.
  
  Abstract ↑
66. Teeguarden, Ron. Radiant Health: The Ancient Wisdom of the Chinese Tonic Herbs. Warner Books, NY, 1998, pp. 171-173.
  
  ↑
Articles of Interest from Smart Publications Health & Wellness Update

-Sponsored Ads-

Get safe, fast results: Lower LDL 29% … Lower total cholesterol 21% Increase healthy HDL by 15% or more

HEART HEALTH FACT #1:

HEART HEALTH FACT #2:

HEART HEALTH FACT #3:

HEART HEALTH FACT #4:

Drug companies caught red-handed

Editor's Note:

References

Articles of Interest from Smart Publications Health & Wellness Update